Kalaris Therapeutics, Inc. (NasdaqGM: KLRS)
Health Care · Biotechnology · US
$2.50
-7.41% today · -66.4% 1Y
Kalaris Therapeutics, Inc. (NasdaqGM: KLRS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $64.27M and employs 20 people.
Over the last twelve months the share price has lost 66.4%, trading between 2.51 and 11.88.
Tweenvest scores Kalaris Therapeutics, Inc. across four factors: quality 57/100, value 26/100. Its strongest factor is quality.
KLRS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $64.27M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.06
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $11.88
- 52-week low
- $2.51
- Avg volume (3M)
- —
- Shares outstanding
- 23.80M
- Employees
- 20
- Next earnings
- —
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
- ISIN
- US4829291065
- Founded
- 2019
- Listed since
- Jul 30, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Alps Group IncNasdaqGM: ALPS | $65.73M | $0.37 | -6.51% |
| StemRIMTSE: 4599 | $65.18M | ¥164.00 | -6.29% |
| Anti-Microbial Savior BioteQ Co., Ltd.TPEX: 6864 | $64.44M | NT$54.20 | +7.75% |
| iNtRON Biotechnology, Inc.KOSDAQ: A048530 | $64.34M | ₩2,805.00 | -0.36% |
| MiNK Therapeutics, Inc.NasdaqCM: INKT | $63.48M | $11.00 | -11.58% |
| BIO-FD&C Co.,Ltd.KOSDAQ: A251120 | $63.47M | ₩9,830.00 | +7.20% |
| B&K Corporation LimitedSEHK: 2396 | $62.52M | HK$4.17 | -4.47% |
| EyeGene Inc.KOSDAQ: A185490 | $61.57M | ₩1,918.00 | -1.64% |
Figures last refreshed Oct 4, 2026.